Roche reports very strong performance in the first half of 2019 – Outlook raised

Group sales increase 9% at constant exchange rates and 8% in Swiss francs
Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Hemlibra, Tecentriq and Perjeta
Diagnostics Division sales grow 2%, primarily due to its immunodiagnostics business and overall stronger growth in the second quarter

Webcast replay

Half Year Results 2019

Downloads

Investor updates

All

Published on: 22 August 2019

Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer

Published on: 16 August 2019

FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Published on: 5 August 2019

Invitation to Roche’s Pharma Day - Monday, 16th September 2019

IR events

All

4September

Goldman Sachs Medtech Conference

(GMT)

London, UK

add to calendar

5September

UBS Best of Switzerland Conference

(CET)

Zurich, Switzerland

add to calendar

9September

Morgan Stanley Global Healthcare Conference

(EST)

New York, USA

add to calendar

Share price

Latest annual report

Annual Report 2018 Highlights

How digital innovation increases patient benefit in the future

Pipeline

Get up-to-date information about our pipeline.

Roche R&D

Genentech Biooncology

Diagnostics overview

Get an introduction to our Diagnostics business.

Sustainability download center

Sustainability at Roche

Non-financial reporting

Dividend calendar

Timetable for payment of the 2018 dividend

Total return center

Investor tool providing analysis of total returns

FAQ

Get answers to frequently asked questions

How to invest

Message from our CEO

“The foundation of our success is and will remain our clear focus on innovation.”

Roche reports very strong performance in the first half of 2019 – Outlook raised

Half Year Results 2019

Downloads

Related links

Investor updates

Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer

FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Invitation to Roche’s Pharma Day - Monday, 16th September 2019

IR events

Goldman Sachs Medtech Conference

UBS Best of Switzerland Conference

Morgan Stanley Global Healthcare Conference

Share price

Latest annual report

Annual Report 2018 Highlights

Historic quarterly reporting

Finance information tool

Pipeline

Pipeline

Roche R&D

Genentech Biooncology

Diagnostics

Diagnostics overview

Sustainability

Sustainability download center

Sustainability at Roche

Non-financial reporting

Dividend and total return

Dividend calendar

Total return center

Additional share data

FAQ

US investors

How to invest

Message from our CEO

Contact

For all general enquiries

For IR requests

For all general enquiries

For IR requests